Search

Additional file 5. Primary end point analyses of mean and sum scores of FSS-9 at baseline and EOT12 Legends: The table displays the mean and sum scores of FSS-9 at baseline and EOT12 among participants who were included in the intention-to-treat and per-protocol analyses, respectively. The FSS-9 sum score ranges from 9 points, no fatigue, to 63 points, worst fatigue. Each item was ranged on a Likert scale from 1 point, no fatigue, to 7 points, worst fatigue. EOT12: 12 weeks after the end of treatment; SD: Standard deviation.

Additional file 2. The US-English and the Norwegian versions of the FSS-9. Legends: FSS-9; Nine-items Fatigue Severity Scale. All items in the FSS-9 are ranged as a Likert scale from 1 to 7, where 1 indicates “strongly disagree” and 7 indicates “strongly agree”.

Additional file 1. Norwegian national HCV treatment guidelines during the study period.

Additional file 7. A linear prediction of changes in FSS-9 sum scores from baseline to EOT12. Legends: The figure displays the linear predictionincluding 95 % confidence intervals of changes in FSS-9 sum scorefrom baseline to EOT12 for integrated and standard HCV treatment groups. EOT12: 12 weeks after the end of HCV treatment; FSS-9: Nine-item fatigue severity scale; HCV: Hepatitis C virus.

Additional file 8. Pen’s parades of FSS-9 sum scores at baseline and EOT12. Legends: The figures display participants who received integrated and standard HCV treatment and were included in the per-protocol analysis. The graphs demonstrate the FSS-9 sum scores at baseline/prior to the HCV treatment and EOT12. The red line represents the FSS-9 sum scores at baseline when the participants are in sorted order by FSS-9 sum scores to highestscore). The blue spikes demonstrate the FSS-9 sum score at EOT12. The length of the spikes mark the changes in the FSS-9 sum score from baseline to EOT12. Participants without spikes did not complete FSS-9 assessment at EOT12. The dotted line demonstrates the cut-off value for severe fatigue. EOT12: 12 weeks after the end of treatment; FSS-9: Nine-item Fatigue Severity Scale.

Additional file 3. The relationship between adults ADHD self-report scale version 1.1, part A (ASRS-A), and clinically diagnosed ADHD (presented by numbers in each category). Legends: ADHD: Attention-deficit/hyperactivity disorder; ASRS-A: The adults ADHD self-report scale version 1.1, part A. ASRS-A + and ASRS-A – were defined as exceeding and not reaching the symptom cutoff for at least four of six questions in the ASRS, part A, respectively. ADHD + and ADHD – were defined as being registered or not registered with a diagnosis of ADHD according to medical records. 1) A total of 10 patients were prescribed central stimulants. 2) A total of one patient was prescribed central stimulants. ASRS-A + and ADHD +: Spearman’s rho = 0.3130. Sensitivity = 29/36 = 0.806; Specificity = 117/189 = 0.619.

Additional file 2. Longitudinal ordinal multilevel mixed-effect logistic regression analysis of the association of ASRS–memory and –attention (combined outcome variable) with sociodemographic characteristics and substance use at baseline and over time (per year). Legends: ADHD: Attention-deficit/hyperactivity disorder; ASRS-A: The adults ADHD self-report scale version 1.1, part A. 1) The combined outcome variable was generated as a sum score of the responses to ASRS, part A, question 3 (ASRS–memory) and ASRS, part B, question 9 (ASRS–attention), ranged from 0 to 8. Patients who completed one health assessment visit and only responded to one of the two ASRS questions were excluded (n = 35). A total of 666 patients responded to ASRS–memory and attention questions. Of those, 241 had completed two or more occasions, rendering 257 repeated responses to the questions. The correlation between ASRS–memory and –attention questions was 0.39. ASRS–memory: How often do you have problems remembering appointments or obligations? ASRS–attention: How often do you have difficulty concentrating on what people say to you, even when they are speaking to you directly? The responses were answered on a Likert scale ranging from never (0) to very often (4) for each question, which generated a sum score from 0 to 8.

Additional file 4. Distribution of FSS-9 sum scores for integrated HCV treatmentand standard HCV treatmentgroups at baseline. Legends: The two graphsdisplay the FSS-9 sum scores for integrated HCV treatmentand standard HCV treatmentat baseline. The red lines demonstrate the distribution of the FSS-9 sum scores with skewness –0.8and –0.5and kurtoses 2.7 and 2.3. The FSS-9 sum scores ranges from 9 points, no fatigue, to 63 points, worst fatigue.

Additional file 1. US-English and Norwegian versions of the Adult ADHD self-report scale version 1.1, part A, and part B, question 9. Legends: ADHD: Attention-deficit/hyperactivity disorder.

Additional file 6. Linear mixed model of ΔFSS-9 sum score from baseline to EOT12 for integrated HCV treatment (per-protocol) (number of participants = 212, number of observations: 424). Legends: The table displays a linear mixed model analysis (Restricted Maximum Likelihood) regression of the impact of integrated HCV treatment on changes in FSS-9 sum scores (ΔFSS-9 sum scores) from baseline to EOT12 (per-protocol analysis), adjusted for acheiving SVR at EOT12. The FSS-9 sum score ranges from 9 points, no fatigue, to 63 points, worst fatigue. EOT12: 12 weeks after the end of HCV treatment; FSS-9: Nine-item fatigue severity scale.

Additional file 9. Linear mixed model of ΔFSS-9 sum scores from baseline to EOT12 for integrated HCV treatment (intention-totreat, sensitivity analysis without computed data), adjusted for SVR at EOT12 (number of participants = 189, number of observations: 378). Legends: The table displays a linear mixed model analysis (Restricted Maximum Likelihood) regression of the impact of integrated HCV treatment and SVR on changes in FSS-9 sum scores (ΔFSS-9 sum score) from baseline to EOT12 (intention-to-treat analysis without computed data by the expectation–maximization algorithm). The FSS-9 sum score ranges from 9 points, no fatigue, to 63 points, worst fatigue. EOT12: 12 weeks after the end of HCV treatment; FSS-9: Nine-item fatigue severity scale; SVR: Sustained virological response.

Additional file 3. Aspartate aminotransferase to platelet ratio index. Legends: The figure displays the equation to calculate APRI score. AST upper limit of normal range was defined as 45 IU/Land 35 IU/L.